Productivity Loss in Patients With Chronic Diseases: A Pooled Economic Analysis of Hungarian Cost-of-Illness Studies by Rashdan, Omar & Brodszky, Valentin
- Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/vhriEconomic EvaluationProductivity Loss in Patients With Chronic Diseases: A Pooled Economic
Analysis of Hungarian Cost-of-Illness Studies1,2, 2Omar Rashdan, MSc (Pharm), * Valentin Brodszky, MD, PhD
1Doctoral School of Business and Management, Corvinus University of Budapest, Budapest, Hungary; 2Department of Health Economics, Corvinus University of
Budapest, Budapest, HungaryConflict
* Addre
Budape
2212-10
article u
https://A B S T R A C T
Objectives: To assess productivity loss (PL) variations across a set of chronic diseases and analyze significant PL drivers
(demographics, health status, healthcare resource use) in Hungary.
Methods: Data from 11 cost-of-illness studies (psoriasis, dementia, systemic sclerosis, multiple sclerosis, benign prostatic
hyperplasia, Parkinson’s disease, psoriatic arthritis, rheumatoid arthritis, schizophrenia, epilepsy, and diabetes) were
pooled, and patient-level data were analyzed. A weighted multiple linear regression analysis was run to identify
significant PL indicators. All costs were adjusted to 2018 euro rates and PL was further presented as a proportion of gross
domestic product/capita, facilitating results comparability and transferability.
Results: The dataset comprised 1888 patients from 11 chronic diseases. The average indirect cost/(gross domestic product/
capita) ratio was highest in schizophrenia (72.4%) and rheumatoid arthritis (71.3%) and lowest in benign prostatic hyperplasia
(1.6%). Correlation results infer that a higher EuroQol 5-dimension 3-level index score was significantly associated with lower
PL. The number of hospital admissions was the main contributor toward increasing PL among resource use indicators. Age
and sex showed inconsistent and insignificant correlations with PL. In regression analysis, a better EuroQol 5-dimension
3-level index score and higher education were consistently associated with decreasing PL in all models.
Conclusions: This article will enable health decision makers to understand the importance of adopting a societal perspective
for chronic disease reimbursement decisions. The correlation between PL and health status supports that timely started
effective treatments may prevent patients from losing their workability.
Keywords: benign prostatic hyperplasia, diabetes, dementia, epilepsy, Hungary, productivity loss, indirect cost, multiple
sclerosis, psoriasis, systemic sclerosis, Parkinson’s disease, psoriatic arthritis, rheumatoid arthritis, schizophrenia.
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As a basic term, productivity is simply a measure of output per
unit of input. For health professionals, the term productivity loss
(PL) is defined as the output loss due to health issues corre-
sponding to reduced work output by the productive person,
whether paid or unpaid.1 Direct treatment costs of chronic dis-
eases are rapidly increasing and are only expected to keep
increasing with the continuous development of the new costly yet
effective biologic agents.2 This has been placing an increasing
pressure on policy makers to reimburse the most socially sus-
tainable health interventions. Therefore, considerable attention to
the adoption of a societal perspective in health economic evalu-
ations is starting to emerge.3 Although a societal perspective inof interest: The authors have nothing to disclose.
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doi.org/10.1016/j.vhri.2020.07.572health economic evaluation is often not mandatory, the inclusion
of such costs into health economic evaluations can maximize so-
cial welfare in the long run.4 In 2016, The Netherlands released its
updated pharmacoeconomic guidelines mandating the conduc-
tion of health economic analysis from a societal perspective. These
guidelines also go further to specify the use of friction cost as the
prescribed productivity cost estimation method.5,6 More countries
are expected to imitate The Netherlands’ pharmacoeconomic
guidelines and start mandating a societal perspective in health
economic evaluations.
One prevalent issue in PL evaluations is the weak international
transferability of the results owing to the fragile standardization of
current indirect costs reporting methodologies. Knies et al7
investigated the weak PL transferability issue and found that theiness and Management, Corvinus University of Budapest, Fövám tér 8, 1093
omics and outcomes research. Published by Elsevier Inc. This is an open access
-nd/4.0/).
Table 1. Characteristics of the included COI studies: language, costing year, PL methods, gross income, and wage rate.
Disease Reference Language Costing
year
Measurement
method of
productivity
loss hours
Presenteeism
inclusion
Valuation of
productivity
loss (HCA, FCA,
Both)
Gross
income at
costing year
(euro/month)
Gross wage
rate to
2018 (%)*
Benign prostatic
hyperplasia
9 English 2014 WPAI Yes HCA 989 95.6
Dementia 10 English 2007 Open question No HCA 993 96.0
Diabetes 11 Hungarian 2003 Open question No HCA 653 63.1
Epilepsy 12 Hungarian 2009 Open question No HCA 957 92.5
Multiple sclerosis 13 English 2009 Open question No HCA 957 92.5
Parkinson’s disease 14 English 2009 Open question No HCA 957 92.5
Psoriasis 15 English 2012 WPAI No Both 1054 101.9
Psoriatic arthritis 8 English 2007 Open question No HCA 996 96.3
Rheumatoid arthritis 16 English 2004 Open question No HCA 490 47.4
Schizophrenia 17 Hungarian 2009 Open question No HCA 957 92.5
Systemic sclerosis 18 English 2006 Open question No HCA 913 88.3
FCA indicates friction cost approach; HCA, human capital approach; WPAI, Work Productivity and Activity Impairment.
*Average nominal gross wage in 2018 in Hungary was 1034.5 euros (Source: Hungarian Statistical Office website23).
76 VALUE IN HEALTH REGIONAL ISSUES SEPTEMBER 2020complication starts from the absence of international consensus
on the inclusion of the societal perspective in health economic
evaluations. Moreover, whenever a societal perspective is to be
adopted, differences in PL measurement and valuation methods
further contribute to the results transferability complexity. For
example, either costs or quality-adjusted life-years are usually
adopted for PL valuation; this alone imposes a major hurdle on
results transferability and could result in many complications and
errors, such as double counting when converting the results be-
tween costs and quality-adjusted life-years and vice versa.
The objective of this article is to assess the PL variations across
a set of chronic diseases and analyze PL drivers (demographics,
health status, healthcare resource use) in Hungarian patients. Such
economic analysis can aid health policy makers in visualizing the
PL impact on chronic disease patients, by directly demonstratingTable 2. Disease-specific demographics, resource use, health status,
Disease name Total number
of patients
Number of
patients
below 64
Age mean
(95% CI)
H
e
p
Benign prostatic
hyperplasia
246 49 70.59 (69.56-71.61)
Dementia 88 6 77.55 (75.75-79.37)
Diabetes 480 331 52.56 (51.08-54.05)
Epilepsy 100 97 36.65 (34.16-39.14)
Multiple sclerosis 68 67 37.96 (35.74-40.17)
Parkinson’s disease 110 55 63.28 (61.15-6541)
Psoriasis 200 157 50.66 (48.83-52.50)
Psoriatic arthritis 183 149 50.15 (48.25-52.04)
Rheumatoid arthritis 255 182 55.45 (53.93-56.97)
Schizophrenia 78 73 44.24 (41.30-47.19)
Systemic sclerosis 80 56 57.39 (55.25-59.52)
Total 1888 1222 55.17 (54.44-55.91)the monetary value of adopting a societal perspective for reim-
bursement decisions. Moreover, to enhance the transferability of
our findings, all costs were calculated and presented in unified,
adjusted monetary terms (ie, PL as a percentage of gross domestic
product [GDP]/capita in 2018), facilitating comparisonwith similar
international cost-of-illness (COI) studies.Methods
Data Sources and Tools
This study uses data from 11 noninterventional, cross-
sectional, retrospective COI studies conducted in different medi-
cal centers in Hungary between 2003 and 2015. Our analysis
encompassed the following 11 chronic diseases: psoriaticadjusted indirect cost, and indirect cost as a percent of total cost.
igher
ducation
atients N (%)
Female N (%) EQ-5D-3L
index (95% CI)
Disease
duration in
years
(95% CI)
74 (30%) 0 (0.0) 0.85 (0.83-0.88) 5.56 (4.95-6.18)
12 (14%) 52 (59.1) 0.39 (0.32-0.46) 4.32 (3.11-5.53)
N/A* 267 (55.6) 0.77 (0.74-0.79) 15.60 (13.72-15.48)
18 (18%) 58 (58.0) 0.78 (0.74-0.86) 15.45 (13.04-17.87)
28 (42%) 48 (70.6) 0.67 (0.60-74) 7.02 (5.55-8.48)
40 (36%) 36 (32.7) 0.58 (0.52-0.63) 8.22 (7.10-9.33)
40 (20%) 64 (32.0) 0.69 (0.65-74) 21.44 (19.80-23.08)
43 (24%) 105 (57.4) 0.47 (0.42-52) 9.24 (7.89-10.59)
42 (17%) 218 (85.5) 0.46 (0.42-0.50) 9.10 (7.92-10.27)
9 (12%) 36 (46.2) 0.64 (0.57-0.71) N/A*
16 (20%) 72 (90.0) 0.58 (0.52-0.64) 7.16 (5.69-8.64)
248 956 (50.6) 0.66 (0.64-0.67) 11.40 (10.92-11.88)
ECONOMIC EVALUATION 77arthritis,8 benign prostatic hyperplasia (BPH),9 dementia,10 dia-
betes,11 epilepsy,12 multiple sclerosis,13 Parkinson’s disease,14
psoriasis,15 rheumatoid arthritis,16 schizophrenia,17 and systemic
sclerosis.18 Patient-level raw data on demographics, health-related
quality of life, resource use, and productivity loss for each disease
were collected directly from the patients (or caregivers in case of
dementia) by the department of health economics at Corvinus
University of Budapest, and were later combined for this work.
EuroQol 5-dimension 3-level (EQ-5D-3L) index scores were
measured using the validated Hungarian version. The EQ-5D-3L is
a group of instruments used to provide a perception of health
state, has been used and validated in many disease areas over the
past 30 years,19 and is the health status tool of choice recom-
mended by many health technology assessment organizations.20
Local ethical approvals were obtained if the COI was conducted
in a single institution, while national ethical approval was ac-
quired in case the study was conducted in different medical
centers within the country. All patients signed an informed con-
sent form. Specific information on each included COI study, such
as costing year, gross wage, productivity loss measurement
method (Work Productivity and Activity Impairment [WPAI] or
open question), and the adopted costing approach (ie, human
capital or friction cost) were extracted by the authors from the
relevant publications. The WPAI questionnaire is an instrument
developed to measure a patient’s impairment owing to a health
condition, for both paid (absenteeism and presenteeism) and
unpaid work.21 The human capital approach (HCA) and the friction
cost approach are the 2 dominating methods used for the valua-
tion of PL in paid work and are preferred given their simple, direct
monetary results. Both methods have specific limitations and
advantages and are discussed elsewhere.22
Costing
Cost-of-illness calculations were performed from a societal
perspective (including direct medical, direct nonmedical, and in-
direct costs). All COI studies applied similar methods to measure
time off work and resource use. Patients (or caregivers in de-
mentia) were asked about sick leaves and their employment sta-
tus, including whether they were entitled to disability pension
owing to the disease. Indirect costs for each disease wereNumber of
outpatient visits
mean (95% CI)
Number of
GP visits mean
(95% CI)
Number of
hospital admission
mean (95% CI)
Numbe
missed
hours
mean
6.60 (5.63-7.57) 1.04 (0.63-1.45) 1.08 (0.97-1.19) 35.67
1.15 (0.85-1.44) 0.85 (0.64-1.07) 0.11 (0.05-0.18 104.65
5.45 (5.02-5.88) 7.29 (6.69-7.89) N/A* 187.99
3.52 (2.63-4.41) 3.27 (2.25-4.28) 0.44 (0.11-0.76) 214.96
3.02 (2.16-3.87) 1.33 (0.80-1.86) 0.49 (0.32-0.65) 405.61
4.86 (3.77-5.96) 3.22 (2.41-4.03) 0.42 (0.28-0.55) 381.20
1.61 (1.24-1.98) 4.26 (3.05-5.47) 1.72 (1.65-1.78) 206.4
6.38 (5.25-7.52) 3.70 (2.87-4.54) 0.64 (0.51-0.78) 505.21
7.78 (6.87-8.70) 8.99 (8.11-9.87) 1.09 (0.93-1.25) 1636.69
14.91 (11.26-18.56) 1.76 (0.57-2.94) N/A* 1659.56
7.14 (5.44-8.83) 10.26 (8.92-11.60) 4.61 (3.94-5.29) 1023.02
5.64 (5.32-5.97) 4.74 (4.44-5.04) 1.15 (1.06-1.25) 509.32
EQ-5D-3L indicates EuroQol 5-dimension 3-level index; GP, general practitioner.
*N/A: Data missing from the original database.
Table 2. Continuedcalculated separately by multiplying the number of lost productive
hours with the national gross wage in the corresponding study
year. Adjusted indirect costs were then calculated for each disease
to reflect the value in 2018 euro rates by dividing the average gross
wage for 2018 by the average gross wage for the study year to
obtain a specific conversion factor, which was then multiplied
with the corresponding disease indirect cost to obtain the
adjusted PL costs in unified 2018 euro rates. Furthermore, indirect
costs were expressed as a percentage of GDP per capita for 2018
(indirect costs[GDP/capita]) by dividing each disease’s adjusted
indirect cost by the national GDP/capita in Hungary for 2018. The
average national gross wage in Hungary for 2018 was acquired
from the Hungarian Central Statistical Office website,23 which
amounted to Hungarian forint 329 900 = 1034.5 euros (318.9
Hungarian forint = 1 euro). Similarly, the 2018 Hungarian GDP/
capita (13 686 euros) was obtained from the Hungarian Central
Statistical Office website.24
Statistical Methods and Study Variables
SPSS 23 software (SPSS Inc, Chicago, IL, USA) was used for data
management and statistical analysis. The attributes investigated in
our analysis fall into 4 categories: PL variables (ie, number of
missed working hours and indirect costs), demographic variables
(ie, age, sex, and education level), resource use variables (ie,
number of general practitioner [GP] visits, number of outpatient
visits, number of hospital admissions, and informal care use), and
health status variables (disease duration, EQ-5D-3L index). Dis-
ease dummy variables for each disease were also created to
address the association (if any) between any specific disease and
PL. To measure the sex (male/female), educational level (univer-
sity degree/no university degree), and informal care (received/did
not receive) impact on PL, analysis of variance was used to
compare disease group means of lost productive hours for each
subgroup, whereas Spearman’s rho was employed to identify
significant correlations between resource use, health status, and
age variables and PL.
Weighted linear regression analysis was also run to identify
significant PL indicators and construct a predictive model for PL in
chronic disease patients in Hungary. A weighting variable was
calculated to account for the differences in the sample sizer of
working
per year
(95% CI)
Adjusted indirect
cost in euros
(2018 rates)
Indirect cost
as a percent of
total cost
(7.42-63.92) 213.01, (44.28-381.74) 23.2
(29.26-180.04) 624.51, (174.61-1074.40) 15.0
(138.04-237.94) 1121.2, (823.31-1419.11) 46.1
(135.62-294.29) 1283.94, (810.05-1757.79) 49.1
(225.93-585.28) 2422.67, (1349.48-3495.85) 20.6
(227.21-535.20) 2276.91, (1357.12-3196.69) 34.9
(126.8-286.0) 1231.85, (756.86-1706.85) 14.1
(380.88-629.53) 3015.11, (2273.13-3757.08) 52.1
(1389.78-1883.59) 9763.06, (8290.25-11235.86) 67.4
(1474.66-1844.46) 9912.5, (8808.1-11016.22) 66.1
(789.94-1256.11) 6103.74, (4713.06-7494.42) 56.0
(460.06-558.59) 2464.03, (2243.12-2684.95) 43.3
Table 3. Disease-specific relationship of PL (hours lost/year) with demographics, resource use, and health status indicators.
Disease name Correlation with lost productive hours
GP visit Hospital admissions Outpatient visits EQ-5D-3L index Age (all) Age (,64)
Spearman’s rho (P)
Benign prostatic hyperplasia –0.027 (0.677) 0.962 (0.000) –0.010 (0.881) 0.116 (0.074) –0.321 (0.000) –0.107 (0.465)
Dementia –0.001 (0.990) 0.275 (0.010) 0.082 (0.447) –0.074 (0.495) 0.118 (0.276) N/A*
Diabetes 0.040 (0.416) N/A –0.085 (0.064) –0.232 (0.000) 0.001 (0.985) 0.133 (0.014)
Epilepsy 0.203 (0.073) 0.199 (0.068) 0.197 (0.050) –0.531 (0.000) 0.448 (0.000) 0.488 (0.000)
Multiple sclerosis 0.240 (0.051) 0.428 (0.000) 0.219 (0.079) –0.306 (0.011) 0.231 (0.060) 0.231 (0.060)
Parkinson’s disease 0.234 (0.14) 0.207 (0.030) 0.066 (0.492) –0.141 (0.160) –0.567 (0.000) –0.421 (0.001)
Psoriasis –0.011 (0.873) –0.256 (0.000) 0.049 (0.498) –0.112 (0.121) –0.137 (0.056) –0.040 (0.614)
Psoriatic arthritis 0.197 (0.008) 0.173 (0.019) 0.136 (0.066) –0.196 (0.009) –0.164 (0.028) 0.059 (0.468)
Rheumatoid arthritis 0.255 (0.000) 0.124 (0.049) 0.116 (0.068) –0.131 (0.040) –0.401 (0.000) –0.132 (0.073)
Schizophrenia –0.035 (0.761) N/A 0.054 (0.639) –0.226 (0.046) 0.110 (0.340) 0.424 (0.000)
Systemic sclerosis –0.005 (0.968) 0.207 (0.066) 0.056 (0.622) –0.153 (0.176) 0.284 (0.011) –0.206 (0.127)
78 VALUE IN HEALTH REGIONAL ISSUES SEPTEMBER 2020between diseases, by dividing 100 by the number of patients in
each disease group to obtain a disease-specific value. The result-
ing weight value for each disease was then incorporated into our
models as the regression weighting variable, omitting the effect of
sample size in our models. Owing to some missing information in
our database; 4 regression models were constructed in which the
number of missed working hours per year was the dependent
variable, and BPH was the reference variable (constant), given that
it imposes the lowest PL among investigated diseases. The dif-
ference among the 4 models is as follows: the first 2 models
(models 1 and 2) included all the 1 disease populations with the
following independent variables—age, disease duration, EQ-5D-3L
index, sex, number of GP visits, and number of outpatient visits—
whereas the latter 2 models (models 3 and 4) excluded diabetes
patients while using 2 additional independent variables (ie,
informal care and education level). Models 1 and 3 used the full
patient population, while models 2 and 4 only used patient
populations under 64 years old, which is the average retirementFigure 1. Indirect cost per patient as a percentage of (GDP/capita) f
BPH indicates benign prostatic hyperplasia.age in Hungary,25 simulating the working population within our
sample.Results
Characteristics of Studies
Three of the 11 COI studies were published in Hungarian lan-
guage and 8 in English. Patient sample sizes ranged between 68
(multiple sclerosis) and 480 (diabetes), whereas the total popu-
lation comprised 1888 patients, including 1222 patients who were
of working age (under 64). The predominant productivity valua-
tion approach adopted was the HCA, with 1 article using both HCA
and friction cost approach together. For all 11 studies, opportunity
cost method was employed using the national gross average wage
for the study year. Simple open question was the dominant PL
measurement method, with only 2 COI studies using the WPAIor each investigated chronic disease.
Sex Education Informal care
Female (male) P Higher (lower) P Received (did not receive) P
Lost hours mean ANOVA Lost hours mean ANOVA N (%) ANOVA
N/A 35.67 N/A 78.71 (17.25) 0.050 0.0 (38.15) 0.513
136.88 (59.76) 0.327 26.50 (116.99) 0.416 120.83 (13.35) 0.358
131.17 (259.12) 0.012 N/A N/A N/A N/A
282.62 (121.52) 0.046 64.94 (247.89) 0.079 739.62 (118.55) 0.000
416.13 (380.36) 0.858 250.33 (474.17) 0.211 856.11 (143.69) 0.000
366.97 (385.72) 0.911 277.38 (440.53) 0.315 522.24 (254.76) 0.086
315.07 (155.25) 0.065 85.52 (236.61)) 0.135 227.38 (204.19) 0.867
526.24 (476.89) 0.700 410.30 (537.79) 0.394 731.76 (368.08) 0.005
1629.39 (1726.37) 0.788 522.51 (1879.07) 0.000 1763.58 (1510.80) 0.314
1646.23 (1670.99) 0.895 1155.25 (1725.34) 0.049 1819.52 (1588.47) 0.253
1077.39 (533.73) 0.165 993.62 (1030.37) 0.901 1131.18 (954.60) 0.466
Note. Significant variables in bold font. N/A, data missing from the original database.
ANOVA indicates analysis of variance; EQ-5D-3L, EuroQol 5-dimension 3-level index; GP, general practitioner.
*Only 6 patients are under 64. Spearman correlation could not be performed.
Table 3. Continued
ECONOMIC EVALUATION 79questionnaire. The characteristics of the investigated COI studies
are summarized in Table 1.
Descriptive Results by Disease
Table 2 summarizes the demographics, health status, and
healthcare resource use for each disease. Overall, patients average
age ranged between 36 and 77 years. Female population
comprised roughly half of the total population, with the highest
percentage among systemic sclerosis patients and lowest in pso-
riasis (apart from BPH). Higher education levels were noticed
among multiple sclerosis patients, while schizophrenia patients
reported the lowest educational levels. Health status score was
highest in BPH and lowest in dementia patients, while psoriasis
patients had the longest disease duration. In resource use,
schizophrenia patients visited outpatient clinics more frequently
than other chronic diseases, while systemic sclerosis patients were
highest in GP visits, and were admitted to hospitals more
frequently than other chronic disease patients.
Regarding disease-specific PL, highest mean of lost productive
hours was attributed to schizophrenia with a yearly average of
1660 lost hours per patient, followed closely by musculoskeletal
diseases (ie, rheumatoid arthritis and systemic sclerosis). Benign
prostatic hyperplasia, on the other hand, caused the lowest lost
productive hours per year among the investigated chronic ill-
nesses. This reflected on the yearly indirect cost means with
schizophrenia on top (9912 euros) followed closely by rheumatoid
arthritis, whereas BPH embarked the lowest indirect costs across
the investigated chronic diseases. Similarly, the average indirect
cost as a percent of GDP/capita was highest in schizophrenia and
rheumatoid arthritis, but lowest in BPH. Lost productive hours and
cost means are summarized in Table 2, and Figure 1 shows a bar
chart of indirect cost as a percentage of GDP/capita for each
investigated chronic disease.
Determinants of PL
Table 3 shows the association of PL with demographic,
resource use, and health status variables. Analysis of variance of
disease PL means revealed that sex differences were significant
only in diabetes and epilepsy, whereas higher education levelsresulted in significant PL in patients with BPH, rheumatoid
arthritis, and schizophrenia. In resource use, we found that a
higher number of hospital admissions significantly increases PL in
BPH, dementia, multiple sclerosis, Parkinson’s disease, psoriasis,
psoriatic arthritis, and rheumatoid arthritis patients, but it
significantly decreases PL in psoriasis patients. A higher frequency
of GP visits was a significant driver for PL in Parkinson’s patients,
whereas the number of outpatient visits was a significant PL driver
in epilepsy and psoriatic arthritis patients. Similarly, patients who
received informal care reported significant PL in epilepsy, multiple
sclerosis, and psoriatic arthritis. Similar but not significant differ-
ences were observed in all other diseases for informal care use.
Overall, resource use variables, where significant, correlated
positively toward lost productive hours, with the number of
hospital admissions as the dominant resource use, indirect cost
driver.
In health status, the EQ-5D-3L index significantly correlated
negatively with PL in diabetes, epilepsy, multiple sclerosis, psori-
atic arthritis, and rheumatoid arthritis, imposing lower PL with
higher scores. As for age impact on PL, patient populations under
64 correlated positively with PL in diabetes, epilepsy, and
schizophrenia, but they correlated negatively with Parkinson’s
disease patients (owing to high average age). On the other hand,
when the whole patient population of all ages was considered, age
correlated positively with epilepsy and systemic sclerosis,
whereas it correlated negatively with BPH, Parkinson’s disease,
psoriatic arthritis, and rheumatoid arthritis patients.
Weighted Regression Modeling
Four predictive models were constructed with resulting R
squared values of 0.354, 0.404, 0.367, and 0.420 for models 1
through 4, respectively. The resulting unstandardized beta co-
efficients and their corresponding significance for our models are
presented in Table 4. In model 1, older age and better health status
(EQ-5D-3L index) significantly decrease PL. Patients with diabetes,
epilepsy, or psoriasis also significantly contribute to decreasing PL.
On the other hand, longer disease duration and more frequent GP
visits, along with being a BPH, rheumatoid arthritis, schizophrenia,
or a systemic sclerosis patient, all significantly contribute to
Table 4. Weighted linear regression models 1 through 4.
Linear regression
Model 1 (all patients) Model 2 (patients ,64) Model 3 (all patients) Model 4 (patients ,64)
Unstandardized
coefficients
P Unstandardized
coefficients
P Unstandardized
coefficients
P Unstandardized
coefficients
P
B B B B
Constant 1238.037 .000 364.536 .145 1367.792 .000 386.283 .181
Age –12.788 .000 2.530 .361 –15.064 .000 2.047 .542
Sex 53.515 .273 60.597 .320 66.489 .250 67.942 .349
Disease duration 11.971 .000 15.406 .000 11.965 .000 14.627 .001
High education - - - - –166.925 .006 –255.823 .001
Number of GP visits
per year
9.920 .020 11.619 .021 5.506 .280 7.938 .186
Number of outpatient
visits per year
3.954 .169 7.767 .026 4.181 .200 7.510 .058
Received informal care - - - - 209.539 .001 273.607 .001
EQ-5D-3L index –473.004 .000 –521.625 .000 –390.339 .000 –408.674 .000
Dementia –54.327 .624 –523.890 .126 –198.042 .126 –705.805 .066
Diabetes –322.717 .006 –208.146 .295 - - - -
Epilepsy –427.851 .001 –135.420 .499 –541.018 .000 –211.540 .356
Multiple sclerosis –183.109 .135 103.524 .591 –318.283 .026 13.168 .952
Parkinson’s disease 90.051 .385 375.498 .052 35.475 .762 314.245 .146
Psoriasis –383.147 .001 –282.779 .150 –430.304 .002 –308.265 .167
Psoriatic arthritis –55.996 .619 126.273 .503 –141.194 .270 61.999 .770
Rheumatoid arthritis 1190.580 .000 1550.241 .000 1102.364 .000 1453.579 .000
Schizophrenia 1061.936 .000 1308.953 .000 932.835 .000 1196.595 .000
Systemic sclerosis 529.563 .000 919.060 .000 466.638 .000 846.501 .000
R squared 0.354 0.404 0.367 0.420
Adjusted R squared 0.347 0.395 0.358 0.407
Note. Variables unstandardized B coefficients and their corresponding significance values. BPH was used as the reference variable for all models (lowest indirect cost).
Significant variables are in bold font. Results are significant at P , .005.
BPH indicates benign prostatic hyperplasia; EQ-5D-3L, EuroQol 5-dimension 3-level index; GP, general practitioner.
80 VALUE IN HEALTH REGIONAL ISSUES SEPTEMBER 2020increasing PL. In contrast, for model 2 (under 64), longer disease
duration, more frequent GP and outpatient visits, along with being
a rheumatoid arthritis, schizophrenia, or a systemic sclerosis pa-
tient, all significantly contribute to increasing PL, whereas only
higher health status scores (EQ-5D-3L index) decrease PL in the
working population.
In model 3, older age, higher education, and better health status
(EQ-5D-3L index), in addition to patients with epilepsy, multiple
sclerosis, or psoriatic arthritis, all significantly contribute to
decreasing PL. On the other hand, longer disease duration, informal
care utilization, along with being a BPH, rheumatoid arthritis,
schizophrenia, or a systemic sclerosis patient all significantly in-
crease PL. In contrast, in model 4 (under 64), longer disease duration,
informal care utilization, in addition to being a rheumatoid arthritis,
schizophrenia, or a systemic sclerosis patient, significantly contribute
to increasing PL, while only higher education and health status
scores (EQ-5D-3L index) decrease PL in the working population.Discussion
In 2012, the World Health Organization announced chronic
diseases as one of the major challenges facing nations worldwidein the current century.26,27 This article presents the largest set of
chronic disease indirect cost results in the Central and Eastern
Europe region. Productivity loss data from 11 COI studies have
been pooled, adjusted, and compared to reflect each disease’s
current total and indirect cost estimates, and were further pre-
sented using internationally transferrable monetary terms. Sig-
nificant healthcare resource use, health status, and demographic
variables driving PL in chronic disease patients were also identi-
fied and quantified. Currently, the responsibility of providing
healthcare services in Hungary for primary care, outpatient care,
and inpatient care lies within the government, whereas the direct
responsibility for financing healthcare services is managed by the
National Health Insurance Fund Administration.28 It is mandatory
for all citizens living in Hungary to take the national health in-
surance; however, private insurance policies can be bought as
well.29 The current Hungarian health economic guideline recom-
mends the analysis to be conducted from the healthcare system
perspective, and later mentions that a societal perspective is only
optional.30
Our PL correlation results infer that a better health status score
was the only indicator with a consistent negative impact on PL
(although not always significant). On the other hand, in resource
use, the number of hospital admissions was the highest
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chronic diseases. This is mainly attributed to the fact that a hos-
pital admission is indicating a more severe disease than other
resource use indicators employed in our analysis (ie, GP visit,
outpatient visit). Age, on the other hand, had mixed PL impacts,
depending on the disease type as well as the age group investi-
gated (under or above 64 years). Although the difference in sex PL
means was apparent in most diseases, it was inconsistent for a
specific sex (eg, diabetes and epilepsy).
Regression modeling revealed that only health status score (ie,
ED-5D-3L) had a consistent, significant negative impact on PL
(decreasing lost productive hours) across all 4 models. Similarly, in
models where education level was accounted for (ie, models 3, 4),
a significant decrease in PL was observed with higher educational
levels. This was addressed by Zimmerman et al,31 who investi-
gated higher education impact on overall health and proposed a
hypothesis that adults with relatively higher levels of education
tend to have greater socioeconomic resources to pursue a healthy
lifestyle, and that they can also be better equipped with the health
literacy level required to draw on later in their lives. As for the role
of sex in PL modeling, none of our 4 predictive models flagged sex
as a significant PL variable. Rather, the main contributor in all of
our 4 models was being a patient of 1 of the 3 most cost-intensive
diseases (ie, schizophrenia and musculoskeletal diseases).
As demonstrated in our article, indirect costs can comprise a
large chunk of the total economic burden of chronic diseases.
Health policy makers often disregard indirect costs for various
reasons, such as the scarcity and complexity of available local
evidence to adopt a societal perspective. Moreover, the weak in-
ternational transferability of health economic evaluations further
imposes more challenges. Heterogeneity of COI reporting is a
major issue in results transferability, mainly arising from the lack
of methodological consensus on perspective, measurement in-
struments, study designs, and valuation methodologies, among
other reasons.32 Devising one universal reporting method for all
diseases can be farfetched given the diverse nature of diseases.
One the other hand, proposals for the standardization of COI
reporting methodologies for a specific disease, although still
scarce, are starting to emerge. Jin and Mosweu,33 for instance,
proposed a specific set of recommendations for schizophrenia COI
reporting and valuation methods. This was done by conducting a
systematic review in which they gathered and analyzed a suffi-
cient number of schizophrenia COI results from multiple authors
and countries to finally come to a consensus for a standard COI
reporting methodology for schizophrenia.
Although indirect cost as a proportion of total cost has been
often employed in health economic evaluations,34,35 this measure
has proven to be inadequate to facilitate the international trans-
ferability of results. For instance, Jin and Mosweu,33 who extracted
this ratio for schizophrenia from multiple COI studies, demon-
strated how the results varied greatly across different countries,
and even within the same country occasionally; schizophrenia’s
indirect cost percentage of total cost fluctuated from as low as 36%
(in Norway) as reported by Evensen et al36 to up to 83% in South
Korea as reported by Chang et al.37 While our costs for schizo-
phrenia resulted in 66% indirect cost proportion from total cost.
Similarly, Blahova et al38 published a COI study for multiple scle-
rosis costs in the Czech Republic with a resulting proportion of
45% indirect costs out of total costs compared with our reported
20%. Hence, it is apparent that the measure indirect cost/total cost
concludes major international discrepancy and can render the
transferability of the results unfeasible.
To address this issue, and building on the assumption that
higher-income countries typically possess a higher capacity to
spend on their health systems and vice versa, it can be beneficialfor indirect costs to be formulated taking into consideration a
national GDP perspective. The measure of indirect cost proportion
out of the national GDP/capita can potentially prove more bene-
ficial for PL results transferability than indirect cost/total cost. To
further simplify the indirect cost/(GDP/capita) utilization, a 3-level
categorization system is proposed; high PL (above 50%), moderate
PL (15%-50%), and low PL (below 15%). To give perspective, our
findings demonstrated that schizophrenia and rheumatoid
arthritis both fall within the high PL disease category. Systemic
sclerosis, multiple sclerosis, Parkinson’s disease, and psoriatic
arthritis all fall within the moderate PL category, whereas de-
mentia, diabetes, epilepsy, psoriasis, and BPH patients fell into the
low PL category. In a similar methodological approach, Zhao et al39
conducted a cross-country secondary analysis for the COI studies
that reported indirect costs using the HCA for a few chronic dis-
eases, one of which was schizophrenia. Their analysis comprised 9
schizophrenia COI studies, and the GDP-adjusted indirect costs
were quantitatively synthesized so that the indirect costs are
presented as a percentage of the national gross domestic product
per capita “indirect cost/(GDP/capita).” Three different indirect
cost/(GDP/capita) means (95% CI) were reported (ie, 66.5% (66.0-
67.0), 79.2% (54.0-104.3), and 79.2% (52.4-117.8), based on 3
modeling approaches (ie, fixed-effect model, random-effect
model, and bootstrapping estimation), respectively. All 3 re-
ported indirect cost/(GDP/capita) means are fairly close to our
reported result for schizophrenia (72.4%), and all are falling into
the high PL category. This demonstrates the usefulness of the
national GDP association with indirect costs for international PL
results transferability.
Some limitations of this study should be mentioned. First,
disease severity and comorbidity data were not taken into
consideration. Second, in our PL modeling for working patient
populations (models 2 and 4), some moderate PL diseases (eg,
dementia and Parkinson’s disease) could be underrepresented in
these models given their late age disease nature. Third, most of the
studies were conducted in tertiary clinical centers, and systematic
selection bias owing to center effects could have been present.
Thus, the results may not be representative of the entire disease
populations. Finally, study data were collected retrospectively
using self-completed questionnaires and, with such data, there is
always a risk of recall bias.Conclusion
Results of our study provide useful monetary insights on PL
impact and drivers in chronic disease patients in Hungary. This
article will enable health decision makers to understand the
importance of adopting a societal perspective for chronic disease
reimbursement decisions. The significant correlation between PL
and health status (ie, EQ-5D-3L index) supports that timely started
effective treatments may prevent people from losing their work-
ability. Schizophrenia and musculoskeletal disease patients had
the highest PL, whereas BPH patients’ PL was the lowest. We also
demonstrated that indirect costs (GDP/capita) can enhance the
international PL comparability and transferability.Acknowledgments
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